Advanced search
Publication Cover
Pain Management Volume 13, 2023 - Issue 11
Submit an article Journal homepage
95
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Gepants in the Acute Management of Migraine

William David Wells-Gatnik1 Department of Clinical & Molecular Medicine, Sapienza University, ItalyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0009-0002-5564-2783
ORCID Icon &
Paolo Martelletti2 Unitelma Sapienza University of Rome, ItalyORCID Iconhttps://orcid.org/0000-0002-6556-4128
ORCID Icon
Pages 627-630 | Received 09 Oct 2023, Accepted 25 Oct 2023, Published online: 09 Nov 2023

References

  • Stovner LJ , HagenK , LindeMet al. The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates. J. Headache Pain23(1), 34 (2022).
  • Steiner TJ , StovnerLJ , JensenRet al. Migraine remains second among the world’s causes of disability, and first among young women: findings from GBD2019. J. Headache Pain21(1), 1–3 (2020).
  • Sacco S , AminFM , AshinaMet al. European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention – 2022 update. J. Headache Pain23(1), 67 (2022).
  • Moreno-Ajona D , Villar-MartínezMD , GoadsbyPJ. New generation gepants: migraine acute and preventive medications. J. Clin. Med.11(6), 3–7 (2022).
  • Dhillon S . Zavegepant: First Approval. Drugs83(9), 825–831 (2023).
  • Bedrin K , AilaniJ. Atogepant for migraine. Drugs Today (Barc)58(8), 399–405 (2022).
  • Eigenbrodt AK , AshinaH , KhanSet al. Diagnosis and management of migraine in ten steps. Nat. Rev. Neurol.17(8), 501–514 (2021).
  • Gendolla A , RauerN , KraemerSet al. Epidemiology, demographics, triptan contraindications, and prescription patterns of patients with migraine: a German claims database study. Neurol. Ther.11(1), 167–183 (2022).
  • Olesen A , SchytzHW , OstrowskiSRet al. Low adherence to the guideline for the acute treatment of migraine. Sci. Rep.12(1), 8487 (2022).
  • Dodick DW . Triptan nonresponder studies: implications for clinical practice. Headache45(2), 156–162 (2005).
  • Limmroth V , KatsaravaZ , FritscheGet al. Features of medication overuse headache following overuse of different acute headache drugs. Neurology59(7), 1011–1014 (2002).
  • Yang C-P , LiangC-S , ChangC-Met al. Comparison of New Pharmacologic Agents With Triptans for Treatment of Migraine: A Systematic Review and Meta-analysis. JAMA Network Open.4(10), e2128544 (2021).
  • Scott LJ . Ubrogepant: First Approval. Drugs80(3), 323–328 (2020).
  • Blair HA . Rimegepant: a review in the acute treatment and preventive treatment of migraine. CNS Drugs37(3), 255–265 (2023).
  • Teall J , TuchmanM , CutlerNet al. Rizatriptan (MAXALT) for the acute treatment of migraine and migraine recurrence. A placebo-controlled, outpatient study. Rizatriptan 022 Study Group. Headache38(4), 281–287 (1998).
  • Ryan R , ElkindA , BakerCCet al. Sumatriptan nasal spray for the acute treatment of migraine. Results of two clinical studies. Neurology49(5), 1225–1230 (1997).
  • Cameron C , KellyS , HsiehSCet al. Triptans in the Acute Treatment of Migraine: A Systematic Review and Network Meta-Analysis. Headache55 (Suppl. 4), 221–35 (2015).
  • Ashina S , TerwindtGM , SteinerTJet al. Medication overuse headache. Nat. Rev. Dis. Primers9(1), 5 (2023).
  • Zebenholzer K , GallW , WöberC. Use and overuse of triptans in Austria – a survey based on nationwide healthcare claims data. J. Headache Pain19(1), 34 (2018).
  • Rissardo JP , CapraraALF. Gepants for acute and preventive migraine treatment: a narrative review. Brain Sci.12(12), 8 (2022).
  • Altamura C , BrunelliN , MarcosanoMet al. Gepants - a long way to cure: a narrative review. Neurol. Sci.43(9), 5697–5708 (2022).
  • Dodick DW , ShewaleAS , LiptonRBet al. Migraine patients with cardiovascular disease and contraindications: an analysis of real-world claims data. J. Primary Care Comm. Health11, 215013272096368 (2020).
  • Wang Q , WangS , ZhuYet al. Clinical efficacy and safety of rimegepant in the treatment of migraine: a meta-analysis of randomized controlled trials. Front Neurol.14, 1205778 (2023).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.